Merz Neurosciences, a division of Merz North America (US affiliate of the global Merz Pharma Group), today announced that Merz has two oral presentations at the 9th World Congress for Neurorehabilitation in Philadelphia, PA, including data for XEOMIN® (incobotulinumtoxinA) in the treatment of adult Upper Limb Spasticity (ULS), the indication for which Merz recently received FDA approval.

“Our mission to deliver better to our customers and patients is accomplished by arming physicians with relevant data and evidence-based treatment approaches,” said Glenn Block, Vice President and Head of Neurosciences. “To that end, we are proud to be presenting our data to this year’s World Congress for Neurorehabilitation meeting attendees on the heels of XEOMIN® (incobotulinumtoxinA) inclusion as a Level A recommendation for use in treatment of focal manifestations of adult ULS in the recent release of the American Academy of Neurology Practice Guideline Update.”

On Wednesday, May 11, 2016, the following two oral presentations will be given in the Franklin 12 room of the Philadelphia Marriott Downtown:

• Sustained Efficacy with IncobotulinumtoxinA in Upper-Limb Post-Stroke Spasticity over 48 Weeks (a Phase 3, Placebo-Controlled Study with Open-Label Extension). Bruce S. Rubin, MD – Design Neuroscience Center, Doral, FL, USA. Abstract # WCNR-0473. 2:20PM to 2:30PM.

• Escalating Doses of IncobotulinumtoxinA (400u-800u) Lead to Increasing Improvements in Disability Due to Multifocal Upper- and Lower-Limb Spasticity. David M Simpson, MD, FAAN – Icahn School of Medicine at Mount Sinai, NY, USA. Abstract # WCNR-0482. 2:30PM to 2:40PM.

Merz Neurosciences is also sponsoring a Meet the Expert Session, which will be held on Thursday, May 12 from 12:30PM-1:30PM in Franklin I and II. The presenter for this event is David M Simpson, MD, FAAN of the Icahn School of Medicine at Mount Sinai.

For more information, please see XEOMIN full Prescribing Information and Medication Guide.

About Merz Neurosciences

Merz Neurosciences is a division of Merz North America, a specialty healthcare company that is dedicated to delivering a better total experience in aesthetics, dermatology, and neurosciences. By working side by side with physicians and patients, Merz Neurosciences strives to deliver meaningful treatment options and a better patient experience in order to meet the needs of each person we serve. Merz Neurosciences is an important contributor to the U.S. neurosciences space, offering a well-balanced product portfolio that includes the neurotoxin Xeomin® (incobotulinumtoxinA), the anticholinergic Cuvposa® (glycopyrrolate) Oral Solution and the Prolaryn ® (injectable implant) family of products.

About XEOMIN® (incobotulinumtoxinA)

Xeomin® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles and used to treat increased muscle stiffness in the arm of adults with upper limb spasticity, the abnormal head position and neck pain that happens with cervical dystonia (CD) in adults, and to treat abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (Botox®).

To learn more about Merz Neurosciences and their U.S. product portfolio, please visit XEOMIN® IMPORTANT CONSUMER SAFETY INFORMATION

Read the Medication Guide before you start receiving XEOMIN® (Zeo-min) and each time XEOMIN® is given to you as there may be new information. The risk information provided here is not comprehensive. To learn more:

• Talk to your health care provider or pharmacist

• Visit to obtain the FDA-approved product labeling

• Call 1-888-4-XEOMIN

Uses XEOMIN® is a prescription medicine that is injected into muscles and used to treat:

• increased muscle stiffness in the arm of adults with upper limb spasticity

• abnormal head position and neck pain in adults with cervical dystonia (CD)

• abnormal spasm of the eyelids (blepharospasm) in adults who have had prior treatment with onabotulinumtoxinA (BOTOX®)

It is not known whether XEOMIN® is safe or effective in children.


XEOMIN® may cause serious side effects that can be life threatening. Call your doctor or get medical help right away if you have any of these problems anytime (hours to week) after treatment with XEOMIN®:

Problems with swallowing, speaking, or breathing can happen within hours to weeks after an injection of XEOMIN® if the muscles that you use to breathe and swallow become weak. Death can happen as a complication if you have severe problems with swallowing or breathing after treatment with XEOMIN®.

Download File:
05.10.2016 [ 0 KB ]

Press Contact

Merz North America

Emily Browder
Corporate Communications


Phone: +1 919.582.8114

Merz in the Americas

Merz has a direct presence in six countries in the Americas, as well as a network of selected professional distribution partners in South and Central America and the Caribbean. Merz in the Americas is headquartered in Raleigh, North Carolina, and has facilities in Mesa, Arizona, Franksville, Wisconsin as well as offices in Toronto, Canada, Mexico City, Bogotá, Colombia, São Paolo, Brazil and Buenos Aires, Argentina.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million. More information is available at

Media Contact – Global

Merz Pharma GmbH & Co. KGaA
Global Corporate Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466

Media Contact – North America

Merz North America, Inc.
Corporate Communications
Emily Browder
Phone: +1 919.582.8114